The history of antiretroviral therapy and of its implementation in resource-limited areas of the world

AIDS

Volumn 26, Issue 10, 2012, Pages 1231-1241

  Vella, Stefano ^a   Schwartländer, Bernard ^b   Sow, Salif Papa ^c   Eholie, Serge Paul ^d   Murphy, Robert L ^e  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b UNAIDS   (Switzerland)

^c Fann Hospital University of Dakar   (Senegal)

^d UNIVERSITÉ FÉLIX HOUPHOUËT BOIGNY   (Côte d’Ivoire)

^e NORTHWESTERN UNIVERSITY   (United States)

Author keywords

AIDS; antiretroviral therapy; HIV; resource limited settings

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; EMTRICITABINE; INDINAVIR; LAMIVUDINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANEMIA; ANTIRETROVIRAL THERAPY; ANTIVIRAL THERAPY; CD4+ T LYMPHOCYTE; COST OF ILLNESS; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EPIDEMIC; FOOD AND DRUG ADMINISTRATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISTORY OF MEDICINE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPODYSTROPHY; LOWEST INCOME GROUP; METABOLIC DISORDER; MONOTHERAPY; MYOSITIS; NAUSEA AND VOMITING; NEPHROLITHIASIS; NEUTROPENIA; PATIENT CARE; PLACENTAL TRANSFER; PRACTICE GUIDELINE; PREGNANT WOMAN; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SURVIVAL; VIRUS LOAD; VIRUS TRANSMISSION;

ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DEVELOPED COUNTRIES; DEVELOPING COUNTRIES; DIDEOXYNUCLEOSIDES; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 84862732933     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32835521a3     Document Type: Review

References (81)

1. Centers for Disease Control (CDC). Pneumocystis pneumonia: Los Angeles. Morb Mortal Wkly Rep 1981; 30:250-252.
2. Centers for Disease Control (CDC). Kaposi's sarcoma and Pneumocystis pneumonia among homosexual men: New York City and California. Morb Mortal Wkly Rep 1981; 30:305-308.
3. Barré-Sinoussi F, Chermann JC, Rey F, Nugeyre MT, Chamaret S, Montagnier L, et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983; 220:868-871. (Pubitemid 13080157)
4. Gallo RC, Salahuddin SZ, Popovic M, Shearer GM, Kaplan M, Haynes BF, et al. Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. Science 1984; 224:500-503. (Pubitemid 14134741)
5. Sandström EG, Kaplan JC. Antiviral therapy in AIDS. Clinical pharmacological properties and therapeutic experience to date. Drugs 1987; 34:372-390; Review.
6. Ward JW, Grindon AJ, Feorino PM, Schable C, Parvin M, Allen JR. Laboratory and epidemiologic evaluation of an enzyme immunoassay for antibodies to HTLV-III. JAMA 1986; 256: 357-361. (Pubitemid 16093267)
7. Furman PA, Fyfe JA, St Clair MH, Weinhold K, Rideout JL, Freeman GA, et al. Phosphorylation of 30-azido-30-deoxythymidine and selective interaction of the 50-triphosphate with human immunodeficiency virus reverse transcriptase. Proc Natl Acad Sci USA 1986; 83:8333-8337. (Pubitemid 17182495)
8. St Clair MH, Richards CA, Spector T, Weinhold KJ, Miller WH, Langlois AJ, et al. 30-Azido-30-deoxythymidine triphosphate as an inhibitor and substrate of purified human immunodeficiency virus reverse transcriptase. Antimicrob Agents Chemother 1987; 31:1972-1977. (Pubitemid 18009571)
9. Fischl MA, Richman DD, Grieco MH, Gottlieb MS, Volberding PA, Laskin OL, et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med 1987; 317:185-191. (Pubitemid 17114872)
10. Fischl MA, Richman DD, Hansen N, Collier AC, Carey JT, Para MF, et al. The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group. Ann Intern Med 1990; 112:727-737. (Pubitemid 20170211)
11. Volberding PA, Lagakos SW, Koch MA, Pettinelli C, Myers MW, Booth DK, et al. Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases. N Engl J Med 1990; 322: 941-949. (Pubitemid 20146627)
12. Lundgren JD, Phillips AN, Pedersen C, Clumeck N, Gatell JM, Johnson AM, et al. Comparison of long-term prognosis of patients with AIDS treated and not treated with zidovudine. AIDS in Europe Study Group. JAMA 1994; 271:1088-1092. (Pubitemid 24106505)
13. Volberding PA, Lagakos SW, Grimes JM, Stein DS, Rooney J, Meng TC, et al. A comparison of immediate with deferred zidovudine therapy for asymptomatic HIV-infected adults with CD4 cell counts of 500 or more per cubic millimeter. AIDS Clinical Trials Group. N Engl J Med 1995; 333:401-407.
14. Fischl MA, Olson RM, Follansbee SE, Lalezari JP, Henry DH, Frame PT, et al. Zalcitabine compared with zidovudine in patients with advanced HIV-1 infection who received previous zidovudine therapy. Ann Intern Med 1993; 118:762-769. (Pubitemid 23135474)
15. Skowron G, Bozzette SA, Lim L, Pettinelli CB, Schaumburg HH, Fischl MA, et al. Alternating and intermittent regimens of zidovudine and dideoxycytidine in patients with AIDS or AIDS-related complex. Ann Intern Med 1993; 118:321-330. (Pubitemid 23070615)
16. Hammer SM, Katzenstein DA, Hughes MD, Gundacker H, Schooley RT, Haubrich RH, et al. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team.NEngl J Med 1996; 335:1081-1090. (Pubitemid 26330961)
17. Delta Coordinating Committee. Delta: a randomised doubleblind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIVinfected individuals. Lancet 1996; 348:283-291.
18. Kuritzkes DR, Marschner I, Johnson VA, Bassett R, Eron JJ, Fischl MA, et al. Lamivudine in combination with zidovudine, stavudine, or didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Disease AIDS Clinical Trials Group Protocol 306 Investigators. AIDS 1999; 13:685-694.
19. Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O'Sullivan MJ, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1994; 331:1173-1180. (Pubitemid 24331334)
20. Montaner JS, Reiss P, Cooper D, Vella S, Harris M, Conway B, et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study. JAMA 1998; 279:930-937. (Pubitemid 28136082)
21. Cameron DW, Japour AJ, Xu Y, Hsu A, Mellors J, Farthing C, et al. Ritonavir and saquinavir combination therapy for the treatment of HIV infection. AIDS 1999; 13:213-224. (Pubitemid 29050409)
22. Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 1997; 337:725-733. (Pubitemid 27417971)
23. Gulick RM, Mellors JW, Havlir D, Eron JJ, Meibohm A, Condra JH, et al. 3-year suppression of HIV viremia with indinavir, zidovudine, and lamivudine. Ann Intern Med 2000; 133:35-39. (Pubitemid 30432542)
24. Walmsley S, Bernstein B, King M, Arribas J, Beall G, Ruane P, et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med 2002; 346:2039-2046. (Pubitemid 34680595)
25. Pantaleo G, Graziosi C, Demarest JF, Butini L, Montroni M, Fauci AS, et al. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 1993; 362:355-358. (Pubitemid 23101310)
26. PiatakMJr, Saag MS, Yang LC, Clark SJ, Kappes JC, Luk KC, et al. High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. Science 1993; 259:1749-1754. (Pubitemid 23114661)
27. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995; 373:123-126.
28. Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, Deutsch P, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995; 373:117-122.
29. Mellors JW, Rinaldo CR Jr, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996; 272:1167-1170. (Pubitemid 26001148)
30. Larder BA, Darby G, Richman DD. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 1989; 243:1731-1734. (Pubitemid 19106971)
31. HirschMS, Conway B, D'Aquila RT, JohnsonVA, Brun-Vézinet F, Clotet B, et al. Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society: USA Panel. JAMA 1998; 279:1984-1991; Review. (Pubitemid 28298278)
32. Polis MA, Sidorov IA, Yoder C, Jankelevich S, Metcalf J, Mueller BU, et al. Correlation between reduction in plasma HIV-1 RNA concentration 1 week after start of antiretroviral treatment and longer-term efficacy. Lancet 2001; 358:1760-1765. (Pubitemid 33153000)
33. CarpenterCC, FischlMA,Hammer SM,HirschMS,JacobsenDM, Katzenstein DA, et al. Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society-USA. JAMA 1996; 276:146-154; Review.
34. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853-860. (Pubitemid 28135961)
35. Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, Miller MD, et al. Efficacy and safety of tenofovir DF vs. stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004; 292:191-201. (Pubitemid 38917996)
36. Gallant JE, DeJesus E, Arribas JR, Pozniak AL, Gazzard B, Campo RE, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006; 354:251-260. (Pubitemid 43113030)
37. Lazzarin A, Clotet B, Cooper D, Reynes J, Arastéh K, Nelson M, et al. Efficacy of enfuvirtide in patients infected with drugresistant HIV-1 in Europe and Australia. N Engl J Med 2003; 348:2186-2195. (Pubitemid 36618129)
38. Lalezari JP, Henry K, O'Hearn M, Montaner JS, Piliero PJ, Trottier B, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 2003; 348:2175-2185. (Pubitemid 36618128)
39. Clotet B, Bellos N, Molina JM, Cooper D, Goffard JC, Lazzarin A, POWER 1 and 2 study groups, et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet 2007; 369:1169-1178.
40. Cooper DA, Heera J, Goodrich J, Tawadrous M, Saag M, Dejesus E, et al. Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection. J Infect Dis 2010; 201:803-813.
41. Lennox JL, DeJesus E, Lazzarin A, Pollard RB, Madruga JV, Berger DS, et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet 2009; 374:796-806.
42. Robbins GK, De Gruttola V, Shafer RW, Smeaton LM, Pettinelli C, Dubé MP, et al. Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med 2003; 349:2293-2303. (Pubitemid 37509737)
43. Yeni P, Cooper DA, Aboulker JP, Babiker AG, Carey D, Darbyshire JH, et al., INITIO Trial International Co-ordinating Committee. Virological and immunological outcomes at 3 years after starting antiretroviral therapy with regimens containing nonnucleoside reverse transcriptase inhibitor, protease inhibitor, or both in INITIO: open-label randomised trial. Lancet 2006; 368:287-298.
44. Bartlett JA, Fath MJ, Demasi R, Hermes A, Quinn J, Mondou E, et al. An updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adults. AIDS 2006; 20:2051-2064; Review. (Pubitemid 44611058)
45. Mocroft A, Phillips AN, Gatell J, Ledergerber B, Fisher M, Clumeck N, EuroSIDA study group, et al. Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study. Lancet 2007; 370:407-413. (Pubitemid 47176633)
46. Steigbigel RT, Cooper DA, Kumar PN, Eron JE, Schechter M, Markowitz M, et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 2008; 359:339-354.
47. Lazzarin A, Campbell T, Clotet B, Johnson M, Katlama C, Moll A, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebocontrolled trial. Lancet 2007; 370:39-48. (Pubitemid 47017467)
48. Ledergerber B, Lundgren JD, Walker AS, Sabin C, Reiss P, et al. Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. Lancet 2004; 364:51-62.
49. Strategies for Management of Antiretroviral Therapy (SMART) Study Group, El-Sadr WM, Lundgren JD, Neaton JD, Gordin F, AbramsD, Arduino RC, et al. CD4Rcount-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355:2283-2296.
50. Arribas JR, Pozniak AL, Gallant JE, Dejesus E, Gazzard B, Campo RE, et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis. J Acquir Immune Defic Syndr 2008; 47:74-78. (Pubitemid 351619372)
51. Sax PE, Tierney C, Collier AC, Fischl MA, Mollan K, Peeples L, et al. Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. N Engl J Med 2009; 361:2230-2240.
52. Molina JM, Andrade-Villanueva J, Echevarria J, Chetchotisakd P, Corral J, David N, et al. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet 2008; 372:646-655.
53. Riddler SA, Haubrich R, DiRienzo AG, Peeples L, Powderly WG, Klingman KL, et al. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med 2008; 358:2095-2106. (Pubitemid 351679596)
54. Arribas JR, Delgado R, Arranz A, Muñoz R, Portilla J, Pasquau J, et al. Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and 2 nucleosides for maintenance therapy of HIV: 96-week analysis. J Acquir Immune Defic Syndr 2009; 51:147-152.
55. Gatell J, Salmon-Ceron D, Lazzarin A, Van Wijngaerden E, Antunes F, SWAN Study Group, et al. Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results. Clin Infect Dis 2007; 44:1484-1492. (Pubitemid 46801594)
56. Dejesus E, Young B, Morales-Ramirez JO, Sloan L, Ward DJ, Flaherty JF, et al. Simplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients. J Acquir Immune Defic Syndr 2009; 51:163-174.
57. Haubrich RH, Riddler SA, DiRienzo AG, Komarow L, Powderly WG, Klingman K, et al. Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitorsparing regimens for initial HIV treatment. AIDS 2009; 23:1109-1118.
58. Arribas JR, Horban A, Gerstoft J, Fätkenheuer G, Nelson M, Clumeck N, et al. The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml. AIDS 2010; 24:223-233.
59. Lima VD, Harrigan R, Bangsberg DR, Hogg RS, Yip B, et al. The combined effect of modern highly active antiretroviral therapy regimens and adherence on mortality over time. J Acquir Immune Defic Syndr 2009; 50:529-536.
60. van Sighem AI, Gras LA, Reiss P, Brinkman K, de Wolf F, ATHENA national observational cohort study. Life expectancy of recently diagnosed asymptomatic HIV-infected patients approaches that of uninfected individuals. AIDS 2010; 24: 1527-1535.
61. Kitahata MM, Gange SJ, Abraham AG, Merriman B, Saag MS, Justice AC, et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med 2009; 360:1815-1826.
62. When To Start Consortium, Sterne JA, May M, Costagliola D, de Wolf F, Phillips AN, Harris R, et al. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet 2009; 373:1352-1363.
63. Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in highincome countries: a collaborative analysis of 14 cohort studies. Lancet 2008; 372:293-299.
64. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. October 14, 2011; 1-167. Available at http://www. aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf.
65. Montaner JS, Lima VD, Barrios R, Yip B, Wood E, Kerr T, et al. Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. Lancet 2010; 376:532-539.
66. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365:493-505.
67. Marin B, Thiébaut R, Bucher HC, Rondeau V, Costagliola D, Dorrucci M, et al. Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy. AIDS 2009; 23:1743-1753.
68. Capeau J. Premature aging and premature age-related comorbidities in HIV-infected patients: facts and hypotheses. Clin Infect Dis 2011; 53:1127.
69. Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med 2005; 352:48-62; Review. (Pubitemid 40075680)
70. Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, Rao S, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006; 12:1365-1371. (Pubitemid 44924494)
71. Deeks SG. HIV infection, inflammation, immunosenescence, and aging. Annu Rev Med 2011; 62:141-155; Review.
72. Perelson AS, Essunger P, Cao Y, Vesanen M, Hurley A, Saksela K, et al. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 1997; 387:188-191. (Pubitemid 27209434)
73. Chun TW, Fauci AS. Latent reservoirs of HIV: obstacles to the eradication of virus. Proc Natl Acad Sci USA 1999; 96:10958-10961. (Pubitemid 29487311)
74. Chun TW, Carruth L, Finzi D, Shen X, DiGiuseppe JA, Taylor H, et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 1997; 387:183-188. (Pubitemid 27209433)
75. Chun TW, Nickle DC, Justement JS, Meyers JH, Roby G, Hallahan CW, et al. Persistence of HIV in gut-associated lymphoid tissue despite long-term antiretroviral therapy. J Infect Dis 2008; 197:714-720. (Pubitemid 351364472)
76. Finzi D, Blankson J, Siliciano JD, Margolick JB, Chadwick K, Pierson T, et al. Latent infection of CD4R T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 1999; 5:512-517. (Pubitemid 29220209)
77. Richman DD, Margolis DM, Delaney M, Greene WC, Hazuda D, Pomerantz RJ. The challenge of finding a cure for HIV infection. Science 2009; 323:1304-1307.
78. Schwartländer B, Stover J, Walker N, Bollinger L, Gutierrez JP, McGreevey W, et al. Resource needs for HIV/AIDS. Science 2001; 292:2434-2436. (Pubitemid 32601643)
79. Hogg R, Cahn P, Katabira ET, Lange J, Samuel NM, O'Shaughnessy M, et al. Time to act: global apathy towards HIV/AIDS is a crime against humanity. Lancet 2002; 360:1710-1711. (Pubitemid 35447895)
80. Saunders KO, Rudicell RS, Nabel GJ. The design and evaluation of HIV-1 vaccines. AIDS 2012; 26:1293-1302.
81. Laga M, Piot P. Prevention of sexual transmission of HIV: real results, science progressing, societies remaining behind. AIDS 2012; 26:1223-1229.